Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in
treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine
and venetoclax, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
bendamustine, obinutuzumab, and venetoclax may work better in treating patients with mantle
cell lymphoma.